EP Patent

EP1806131A3 — Use of sex steroid function modulators to treat wounds and fibrotic disorders

Assigned to Renovo Ltd · Expires 2007-08-01 · 19y expired

What this patent protects

The present application relates to the use of compounds that influence the sex hormone system for the treatment of wounds and/or fibrotic disorders. Preferred compounds for use in such treatments are steroid hormones and especially the oestrogens.

USPTO Abstract

The present application relates to the use of compounds that influence the sex hormone system for the treatment of wounds and/or fibrotic disorders. Preferred compounds for use in such treatments are steroid hormones and especially the oestrogens.

Drugs covered by this patent

Patent Metadata

Patent number
EP1806131A3
Jurisdiction
EP
Classification
—
Expires
2007-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Renovo Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.